Biotech

Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today reported financial results for 2017 and provided a corporate update. As quoted in the press release: “We made significant progress throughout 2017 advancing our pipeline and PDC therapeutic platform both through our own clinical development …

Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today reported financial results for 2017 and provided a corporate update.

As quoted in the press release:

“We made significant progress throughout 2017 advancing our pipeline and PDC therapeutic platform both through our own clinical development programs and through strategic collaborations. Our Phase 2 study for R/R MM and other B-Cell malignancies continues to move forward and we continue to be pleased with the results of our ongoing Phase 1 clinical trial of CLR 131 as a treatment for advanced MM,” said James Caruso, president and CEO of Cellectar Biosciences. “We expect to achieve a number of important milestones in the coming months that should position us well for continued progress throughout the balance of 2018 and beyond.”

Click here to read the press release.

Featured

MARKETS

Markets
TSX20124.46-57.46
TSXV702.42-3.16
DOW31029.53-223.60
S&P 5003868.37-32.42
NASD11265.30-123.19
ASX7064.50-118.20

COMMODITIES

Commodities
Gold1843.50+1.32
Silver21.75-0.15
Copper4.27-0.01
Palladium1961.00-43.00
Platinum955.00-4.00
Oil112.85+0.64
Heating Oil3.66-0.01
Natural Gas8.10-0.21

DOWNLOAD FREE REPORTS

×